Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Thu, 08/31/23 - 06:02 pm
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
Wed, 08/23/23 - 10:06 am
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
Thu, 08/10/23 - 09:54 am
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Spotlight – Nash in 2023 and beyond
EP Vantage
Thu, 08/3/23 - 10:03 am
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
BioSpace
Mon, 07/31/23 - 10:18 am
Intercept Pharma
NASH
obeticholic acid
EASL 2023 – Biomarkers back a new NASH player
EP Vantage
Mon, 06/26/23 - 09:32 am
NASH
89Bio
pefozafermin
Boston Pharmaceuticals
BOS-580
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
Stat
Sun, 06/25/23 - 09:43 pm
ADA
diabetes
NASH
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Thu, 06/22/23 - 10:46 pm
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Wed, 06/21/23 - 10:51 am
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide
BioSpace
Wed, 06/14/23 - 10:08 am
Merck
efinopegdutide
FDA
NASH
fast track
Rosa Biotech accelerates NASH pre-clinical trial in liver disease
Biopharma Reporter
Tue, 06/13/23 - 10:52 pm
Rosa Biotech
bio-sensing
NASH
funding
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Stat
Mon, 06/5/23 - 10:10 am
Akero Therapeutics
efruxifermin
NASH
Ozempic
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
BioSpace
Mon, 05/22/23 - 10:01 pm
Hepion Pharmaceuticals
clinical trials
NASH
rencofilstat
Future of Intercept’s NASH drug in doubt after FDA panel rejection
BioPharma Dive
Sun, 05/21/23 - 10:51 pm
Intercept Pharma
FDA
NASH
obeticholic acid
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
Wed, 05/17/23 - 10:57 pm
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
Promising candidate for NASH submitted to FDA as IND
Clinical Trials Arena
Tue, 04/4/23 - 11:14 pm
NeuroBo
FDA
clinical trials
NASH
89Bio Enlivened by Nash success
EP Vantage
Thu, 03/23/23 - 09:50 am
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
Wed, 03/22/23 - 10:05 am
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
Mon, 03/13/23 - 10:19 am
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »